Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Share-based Compensation (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Share-based Compensation data on record, last reported at $4.4 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 1.91% year-over-year to $4.4 million; the TTM value through Sep 2025 reached $19.0 million, up 7.3%, while the annual FY2024 figure was $18.1 million, 8.74% up from the prior year.
  • Share-based Compensation reached $4.4 million in Q3 2025 per GLUE's latest filing, down from $4.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.3 million in Q1 2025 and bottomed at $4.0 million in Q1 2023.
  • Average Share-based Compensation over 3 years is $4.5 million, with a median of $4.5 million recorded in 2023.
  • The widest YoY moves for Share-based Compensation: up 22.62% in 2024, down 4.16% in 2024.
  • A 3-year view of Share-based Compensation shows it stood at $4.1 million in 2023, then rose by 9.7% to $4.5 million in 2024, then fell by 2.35% to $4.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $4.4 million in Q3 2025, $4.9 million in Q2 2025, and $5.3 million in Q1 2025.